nach oben

Erschienen in:

01.03.2013 | original article

Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria

verfasst von: Evelyne Bareck, Ahmed Ba-Ssalamah, Thomas Brodowicz, Wolfgang Eisterer, Michael Häfner, Christoph Högenauer, Ulrike Kastner, Thomas Kühr, Friedrich Längle, Bernadette Liegl-Atzwanger, Sebastian F. Schoppmann, Gerlig Widmann, Fritz Wrba, Johannes Zacherl, Ferdinand Ploner

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2013

Einloggen, um Zugang zu erhalten

Summary

Optimal treatment for patients suffering from gastrointestinal stromal tumors (GIST) is based on an interdisciplinary treatment approach. Austrian representatives of Medical and Surgical Oncology, Pathology, Radiology, Nuclear Medicine, Gastroenterology, and Laboratory Medicine issued this manuscript on a consensual base within the context of currently available and published literature. This paper contains guidelines and recommendations for diagnosis, therapy, and follow-up of GIST patients in Austria.

Vorheriger Artikel Radiofrequenzablation des hepatozellulären Karzinoms

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Human Pathol. 2002;33:459–65.CrossRef

Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507–19.PubMedCrossRef

Miettinen M, Virolainen M, Maarit Sarlomo R. Gastrointestinal stromal tumors—value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995;19:207–16.PubMedCrossRef

Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature. 1995;373:347–9.PubMedCrossRef

Kindblom L, Ramotti H, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–69.PubMed

Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol. 2000;156(4):1157–63.PubMedCrossRef

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 279:577–80.

Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.PubMedCrossRef

Agaimy A, Terracciano LM, Dirnhofer S, Tornillo L, Foerster A, Hartmann A, Bihl MP. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol. 2009;62(7):613–6.PubMedCrossRef

10.

Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, et al. (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47(10):853–9.PubMedCrossRef

11.

Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133:141–8.PubMedCrossRef

12.

Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.PubMedCrossRef

13.

Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.PubMedCrossRef

14.

Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer. 2005;103:821–9.PubMedCrossRef

15.

Agaimy A, Wünsch PH, Hofstaedter F, Blaszyk H, Rümmele P, Gaumann A, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31:113–20.PubMedCrossRef

16.

Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 2006;37:1527–35.PubMedCrossRef

17.

Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34:1480–91.PubMedCrossRef

18.

Janeway KA, Liegl B, Harlow A, Le C, Perez-Atayde A, Kozakewich H, et al. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha- wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007;67:9084–8.PubMedCrossRef

19.

Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005;29:1373–81.PubMedCrossRef

20.

Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005;27:179–87.PubMedCrossRef

21.

Agaimy A, Hartmann A. Hereditary and non-hereditary syndromic gastointestinal stromal tumours. Pathologe. 2010;31:430–7.PubMedCrossRef

22.

Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, Vanderveer LA, et al. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2009;48:886–96.PubMedCrossRef

23.

Kleinbaum EP, Lazar AJ, Tamborini E, Mcauliffe JC, Sylvestre PB, Sunnenberg TD, et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer. 2008;122:711–8.PubMedCrossRef

24.

Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol. 2005;23:2735–43.PubMedCrossRef

25.

Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol. 2005;29:1170–6.PubMedCrossRef

26.

Maertens O, Prenen H, Debiec-Rychter M, Wozniak A, Sciot R, Pauwels P, et al. Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet. 2006;15:1015–23.PubMedCrossRef

27.

Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30:90–6.PubMedCrossRef

28.

Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999;74:543–52.PubMedCrossRef

29.

Zhang L, Smyrk TC, Young WF, Jr., Stratakis CA, Carney JA. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010;34:53–64.PubMedCrossRef

30.

Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16:79–88.PubMedCrossRef

31.

DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.PubMedCrossRef

32.

Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–89.PubMedCrossRef

33.

Miettinen M, Sobin LH. Gastrointestinal stromal tumors in the appendix: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol. 2001;25:1433–7.PubMedCrossRef

34.

Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52–68.PubMedCrossRef

35.

Miettinen M, Monihan JM, Sarlomo-Rikala M, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol. 1999;23:1109–18.PubMedCrossRef

36.

Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000;13:577–85.PubMedCrossRef

37.

Agaimy A, Wunsch PH. Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg. 2006;391:322–9.PubMedCrossRef

38.

Agaimy A, Markl B, Arnholdt H, Terracciano LM, Dirnhofer S, Hartmann A, et al. Multiple sporadic gastrointestinal stromal tumours arising at different gastrointestinal sites: pattern of involvement of the muscularis propria as a clue to independent primary GISTs. Virchows Arch. 2009;455:101–8.PubMedCrossRef

39.

Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38(Suppl 5):S37–S38.PubMedCrossRef

40.

Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006;23:120–129.PubMedCrossRef

41.

Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 (Suppl 2):S1–S41.PubMed

42.

Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol. 2009;33:218–26.PubMedCrossRef

43.

Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology. 2005;47:41–7.PubMedCrossRef

44.

Hirota S, Isozaki K. Pathology of gastrointestinal stromal tumors. Pathol Int. 2006;56:1–9.PubMedCrossRef

45.

Montemurro M, Dirnhofer S, Borner M, Burkhard R, Demartines N, Furrer M, et al. Diagnose und Behandlung von GIST in der Schweiz. Schweizer Med Forum. 2008;8:544–9.

46.

Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU. Mutation analysis of GIST: increasing significance for risk assessment and effective targeted therapy. Virchows Arch. 2007;451:743–9.PubMedCrossRef

47.

Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009;33:437–46.PubMedCrossRef

48.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites, and differential diagnosis. Semin Diagn Pathol. 2006;23:70–83.PubMedCrossRef

49.

College of American Pathologists (CAP). Cancer Protocols and checklists—GIST. Available at: www.cap.org.

50.

Dow N, Giblen G, Sobin LH, Miettinen M. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol. 2006;23:111–9PubMedCrossRef

51.

Antonescu CR. Targeted therapy of cancer: new roles for pathologists in identifying GISTs and other sarcomas. Mod Pathol. 2008;21 (Suppl 2):S31–6.PubMedCrossRef

52.

Corless CL, Heinrich MC; Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557–86.PubMedCrossRef

53.

Gustafsson BI, Siddique L, Chan A, Dong M, Drozdov I, Kidd M, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973–2004, and current diagnosis and therapy. Int J Oncol. 2008;33:1121–31.PubMed

54.

Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456:111–27.PubMedCrossRef

55.

Casali PG, Blay JY, ESMO/CONTICANET/EUROBONET. Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 (Suppl 5):98–102.CrossRef

56.

Blackstein ME, Corless CL, Ballman KV, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup. Risk assessment for tumor recurrence after surgical resection of localized primary gastrointestinal stromal tumor (GIST): North American Intergroup phase III trial ACOSOG Z9001. Presented at the 2010 Gastrointestinal Cancers Symposium 2010, Orlando, Florida; Abstract No. 6.

57.

Corless CL, Ballman KVC, Antonescu C, et al. American College of Surgeons Oncology Group. Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial ACOSOG Z9001. J Clin Oncol. 2010;28:15s (suppl; abstr 10006).

58.

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–65.PubMedCrossRef

59.

Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.PubMedCrossRef

60.

Hohenberger P, Ronellenfitsch U, Oladeji O, Pink D, Ströbel P, Wardelmann E, Reichardt P.Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour. Br J Surg. 2010;97:1854–9.PubMedCrossRef

61.

Gold JS, Gönen M, Gutiérrez A, Broto JM, García-del-Muro X, Smyrk TC, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol. 2009;10:1045–5.PubMedCrossRef

62.

Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol. 2010;3:461–71.PubMed

63.

Katenkamp D, Katenkamp K. Gastrointestinale Stromatumoren. Diagnose und Malignitätseinschätzung. Chirurg. 2008;79:625–9.

64.

Dietrich CF, Jenssen C. Evidenzbasierte Einsatzmöglichkeiten der Endosonografie. Z Gastroenterol. 2011;49:599–621.PubMedCrossRef

65.

Akahoshi K, Sumida Y, Matsui N, Oya M, Akinaga R, Kubokawa M, et al. Preoperative diagnosis of gastrointestinal stromal tumor by endoscopic ultrasound-guided fine-needle aspiration. World J Gastroenterol. 2007;13:2077–82.PubMed

66.

Fernández-Esparrach G, Sendino O, Solé M, Pellisé M, Colomo L, Pardo A, et al. Endoscopic ultrasound-guided fine-needle aspiration and trucut biopsy in the diagnosis of gastric stromal tumors: a randomized crossover study. Endoscopy. 2010;42:292–9.PubMedCrossRef

67.

Dewitt J, Emerson RE, Sherman S, Al-Haddad M, McHenry L, Cote GA, Leblanc JK. Endoscopic ultrasound-guided Trucut biopsy of gastrointestinal mesenchymal tumor. Surg Endosc. 2011;25:2192–202.PubMedCrossRef

68.

Philipper M, Hollerbach S, Gabbert HE, Heikaus S, Böcking A, Pomjanski N, et al. Prospective comparison of endoscopic ultrasound-guided fine-needle aspiration and surgical histology in upper gastrointestinal submucosal tumors. Endoscopy. 2010;42:300–5.PubMedCrossRef

69.

Polkowski M, Gerke W, Jarosz D, Nasierowska-Guttmejer A, Rutkowski P, et al. Diagnostic yield and safety of endoscopic ultrasound-guided trucut (corrected) biopsy in patients with gastric submucosal tumors: a prospective study. Endoscopy. 2009;41:329–34.PubMedCrossRef

70.

Persson S, Kindblom LG, Angervall L, Tisell LE. Metastasizing gastric epithelioid leiomyosarcomas (leiomyoblastomas) in young individuals with long-term survival. Cancer. 1992;70:721–32.PubMedCrossRef

71.

Valadão M, de Mello EL, Lourenço L, Vilhena B, Romano S, Castro Ldos S. What is the prognostic significance of metastatic lymph nodes in GIST? Hepatogastroenterology. 2008;55:471–4.

72.

Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin North Am. 2009;89:217–33.PubMedCrossRef

73.

Raut CP, Ashley SW. How I do it: surgical management of gastrointestinal stromal tumors. J Gastrointest Surg. 2008;12:1592–9.PubMedCrossRef

74.

Langer C, Schüler P, Becker H, Liersch T. Gastrointestinale Stromatumore aus chirurgischer Sicht. Chirurg. 2008;79:644–9.PubMedCrossRef

75.

Otani Y, Furukawa T, Yoshida M, Saikawa Y, Wada N, Ueda M, et al. Operative indications for relatively small (2–5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery. 2006;139:484–92.PubMedCrossRef

76.

Pitsinis V, Khan AZ, Cranshaw I, Allum WH. Single center experience of laparoscopic vs. open resection for gastrointestinal stromal tumors of the stomach. Hepatogastroenterology. 2007;54:606–8.PubMed

77.

Alam I, Kheradmand F, Alam S, Jamil A, Wilson I, Hurley M. Laparoscopic management of acutely presenting gastrointestinal stromal tumors: a study of 9 cases and review of literature. J Laparoendosc Adv Surg Tech A. 2007;17:626–33.PubMedCrossRef

78.

Privette A, McCahill L, Borrazzo E, Single RM, Zubarik R. Laparoscopic approaches to resection of suspected gastric gastrointestinal stromal tumors based on tumorlocation. Surg Endosc. 2008;22:487–94.PubMedCrossRef

79.

Catena F, Di Battista M, Fusaroli P, Ansaloni L, Di Scioscio V, Santini D et al. Laparoscopic treatment of gastric GIST: report of 21 cases and literature review. J Gastrointest Surg. 2008;12:561–8.PubMedCrossRef

80.

Sexton JA, Pierce RA, Halpin VJ, Eagon JC, Hawkins WG, Linehan DC, et al. Laparoscopic gastric resection for gastrointestinal stromal tumors. Surg Endosc. 2008;22:2583–7PubMedCrossRef

81.

Silberhumer GR, Hufschmid M, Wrba F, Gyoeri G, Schoppmann S, Tribl B, et al. Surgery for gastrointestinal stromal tumors of the stomach. J Gastrointest Surg. 2009;13:1213–9.PubMedCrossRef

82.

Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, Lu D (2009) Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin. 59:145–70.PubMedCrossRef

83.

Kamusella PC, Bethke A, Platzek I, Wiggermann P, Wissgott C, Stroszczynski C (2009) Minimalinvasive Therapieoptionen bei Metastasen gastrointestinaler Stromatumoren. Radiologe. 49:1132–5.PubMedCrossRef

84.

Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol. 2010;33:11–7.PubMedCrossRef

85.

Bale R, Widmann G, Haidu M. Stereotactic Radiofrequency Ablation. Cardiovasc Intervent Radiol Cardiovasc Intervent Radiol. 2011;34:852–6.CrossRef

86.

Bale R, Widmann G, Stoffner DI. Stereotaxy: breaking the limits of current radiofrequency ablation techniques. Eur J Radiol. 2010;75:32–6.PubMedCrossRef

87.

Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14–24.PubMedCrossRef

88.

Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, et al. Phase II trial of neoadjuvant/ adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7.PubMedCrossRef

89.

Heinrich MC, Owzar K, Corless CI, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360–7.PubMedCrossRef

90.

Van Den Abbeele AD. The lessons of GIST – PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13(Suppl 2):8–13.PubMedCrossRef

91.

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Kim HC, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol. 2008;98:27–33.PubMedCrossRef

92.

De Matteo RP, Owzar K, Antonescu CR, Maki R, Demetri GD, McCarter M, et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: The U.S. Intergroup phase II trial ACOSOG Z9000. Gastrointestinal Cancers Symposium 2008; Abstract 8.

93.

DeMatteo R, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised primary gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.PubMedCrossRef

94.

Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced GIST comparing interruption vs. continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–13.PubMedCrossRef

95.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann J, Pink D, Schütte J et al. One vs. Three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–72.PubMedCrossRef

96.

Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–32.PubMed

97.

Demetri GD, von Mehren M, Blanke CD, Van Den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.PubMedCrossRef

98.

Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5.PubMedCrossRef

99.

Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.PubMedCrossRef

100.

Verweij J, Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127–34.PubMedCrossRef

101.

Van Glabbeke MM, Owzar K, Rankin C Simes J, Crowley J, GIST Meta-analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analysis based on 1640 patients. J Clin Oncol. 2007;25(18S):10004.

102.

Debiec-Rychter M, Sciot R, Le Cescne A, Schlemmer M, Hohenberger P, van Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093–103.PubMedCrossRef

103.

Ray-Coquard IL, Bin Bui N, Adenis A, Rios M Sr., Bertucci F, Chabaud S, et al; Groupe Sarcome Francais & Groupe d’Etude des Tumeurs Osseuses (GSF-GETO). Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. J Clin Oncol. 2010;28:15s (suppl; abstr 10032).

104.

Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced GIST crossing over to a daily Imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751–7.PubMedCrossRef

105.

Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44:501–9.PubMedCrossRef

106.

Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141–7.PubMedCrossRef

107.

Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.PubMedCrossRef

108.

George S, Blay JY, Casali PG, Le Cesne A, Stephanson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45:1959–68.PubMedCrossRef

109.

Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA. Developments in targeted therapy of advanced gastrointestinal stromal tumors. Recent Pat Anticancer Drug Discov. 2008;3:88–99.PubMedCrossRef

110.

Reichardt P. Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep. 2008;10:344–9.

111.

Cassier PA, Dufresne A, Arifi S, El Sayadi H, Ray-Coquard I, Bringuier PP, et al. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Curr Gastroenterol Rep. 2008;10:555–61.PubMedCrossRef

112.

Nilsson B, Nilsson O, Ahlmann H. Treatment of gastrointestinal stromal tumours: imatinib, sunitinib—and then? Exp Opin Investig Drugs. 2009;18:457–68.CrossRef

113.

Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, et al. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer. 2011;31 (Epub ahead of print).

114.

Demetri GD, Scott A, Benjamin RS, Bui MM, Casper ES, Conrad EU III, et al. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 2.2010). J Natl Compr Canc Netw. 2010;8:630–74.PubMed

115.

Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 (Suppl 5):v98–102.

116.

Pantaleo MA, Di Battista M, Catena F, Astorino M, Saponara M, Di Scioscio V, et al. Surgical debulking of gastrointestinal stromal tumors: is it a reasonable option after second-line treatment with sunitinib? J Cancer Res Clin Oncol. 2008;134:625–30.

117.

Ruka W, Rutkowski P, Szawlowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, et al. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol. 2009;35:87–91.PubMedCrossRef

118.

Jones RL, McCall J, Adam A, O’Donnell D, Ashley S, Al-Muderis O, et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. Eur J Surg Oncol. 2010;36:477–82.PubMedCrossRef

119.

Avritscher R, Gupta S. Gastrointestinal stromal tumor: role of interventional radiology in diagnosis and treatment. Hematol Oncol Clin North Am. 2009;23:129–70.PubMedCrossRef

120.

Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. Oncologist. 2007;12:719–26.PubMedCrossRef

121.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9.PubMedCrossRef

122.

Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64–74.PubMedCrossRef

123.

Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef

124.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

125.

Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27:3969–74.PubMedCrossRef

126.

Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760–4.PubMedCrossRef

127.

Sabate E. Adherence to long-term therapies: evidence for action. Geneva, World Health Organization 2003.

128.

Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381–8.PubMedCrossRef

129.

Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113:5401–11.PubMedCrossRef

130.

DeMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Medical Care. 2002;40:794–811.CrossRef

131.

Rosen MA. Use of modified RECIST criteria to improve response assessment in targeted therapies: challenges and opportunities. Cancer Biol Ther. 2010;9:20.PubMedCrossRef

Titel: Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria
verfasst von: Evelyne Bareck
Ahmed Ba-Ssalamah
Thomas Brodowicz
Wolfgang Eisterer
Michael Häfner
Christoph Högenauer
Ulrike Kastner
Thomas Kühr
Friedrich Längle
Bernadette Liegl-Atzwanger
Sebastian F. Schoppmann
Gerlig Widmann
Fritz Wrba
Johannes Zacherl
Ferdinand Ploner
Publikationsdatum: 01.03.2013
Verlag: Springer Vienna
Erschienen in: Wiener Medizinische Wochenschrift / Ausgabe 5-6/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI: https://doi.org/10.1007/s10354-013-0187-3

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5-6/2013

Transarterielle perkutane Chemoembolisation beim Leberzellkarzinom

Übersicht: Lebertumore

Liver tumors and loco-regional therapy

Radiologische Diagnostik primärer Lebermalignome

Radiofrequenzablation des hepatozellulären Karzinoms

Stereotaktische Radiofrequenzablation von intrahepatischen cholangiozellulären Karzinomen – eine minimal invasive Alternative zur Leberresektion